Mark Albertini

About

Dr. Mark Albertini is a faculty member in the Division of Hematology, Medical Oncology and Palliative Care within the Department of Medicine at the University of Wisconsin–Madison. He is the founder of the UW Carbone Cancer Center Comprehensive Melanoma Clinic, the director of the UW Carbone Cancer Center Melanoma Disease-Oriented working group, and serves as the Chief of Oncology at the William S. Middleton Memorial Veterans Hospital. Dr. Albertini is a nationally recognized melanoma researcher with a focus on understanding the immunobiology of human malignant melanoma to develop effective immunotherapies. His translational research program involves clinical and laboratory studies, including the use of novel immunotherapies and a preclinical spontaneous canine melanoma model to inform human studies. He has directed melanoma studies investigating chemotherapy, cytokines, monoclonal antibodies, immunocytokines, and DNA vaccines, and leads a laboratory research program exploring immune monitoring and immunocytokines as potential treatments.

Research topics

• Medicine
• Dermatology
• Cancer research
• Ophthalmology
• Internal medicine
• Immunology
• Pathology
• Surgery
• Biology

Selected publications

• Flt3 ligand augments immune responses to anti-DEC-205-NY-ESO-1 vaccine through expansion of dendritic cell subsets

  Nature Cancer · 2020 · 120 citations

  DOI

• Neutrophil‐to‐eosinophil ratio as a biomarker for clinical outcomes in advanced stage melanoma patients treated with <scp>anti‐PD</scp>‐1 therapy

  Pigment Cell & Melanoma Research · 2023-07-07 · 23 citations

  articleOpen access

  Neutrophil-to-lymphocyte ratios (NLR) and eosinophil counts are associated with improved survival in melanoma patients treated with immune checkpoint inhibitors, but no study has investigated neutrophil-to-eosinophil ratios (NER) as a predictive indicator in this population. In this retrospective study evaluating anti-PD-1 treated patients with advanced melanoma, progression-free survival (PFS), overall survival (OS), objective response rates (ORR), and risk of high-grade (grade ≥3) immune-relat…

  PublisherOA PDFDOI

• NK cells propagate T cell immunity following in situ tumor vaccination

  Cell Reports · 2023-12-01 · 15 citations

  articleOpen access

  We report an in situ vaccination, adaptable to nearly any type of cancer, that combines radiotherapy targeting one tumor and intratumoral injection of this site with tumor-specific antibody and interleukin-2 (IL-2; 3xTx). In a phase I clinical trial, administration of 3xTx (with an immunocytokine fusion of tumor-specific antibody and IL-2, hu14.18-IL2) to subjects with metastatic melanoma increases peripheral CD8+ T cell effector polyfunctionality. This suggests the potential for 3xTx to promote…

  PublisherOA PDFDOI

• Administration of intratumoral GD2-directed interleukin-2 immunocytokine and local radiation therapy to activate immune rejection of spontaneous canine melanoma

  Melanoma Research · 2024-05-20 · 6 citations

  articleOpen access1st authorCorresponding

  Canine malignant melanoma provides a clinically relevant, large animal parallel patient population to study the GD2-reactive hu14.18-IL-2 immunocytokine as it is similar to human melanoma and expresses GD2. The objectives of this study were to evaluate safety, radiation fractionation, and identify informative biomarkers of an in-situ tumor vaccine involving local radiation therapy plus intratumoral-immunocytokine in melanoma tumor-bearing dogs. Twelve dogs (six dogs/arm) with locally advanced or…

  PublisherOA PDFDOI

• Development of a next-generation sequencing protocol for the canine T cell receptor beta chain repertoire

  Veterinary Immunology and Immunopathology · 2023-12-12 · 3 citations

  articleOpen accessSenior authorCorresponding
  PublisherOA PDFDOI

Recent grants

• NIH Grant F32CA008397

  NIH · $57k

• NIH Grant R29CA068466

  NIH · $493k · 2001

• NIH Grant K12CA087718

  NIH · $3.8M · 2010

Frequent coauthors

• Paul M. Sondel

  University of Wisconsin–Madison

  150 shared

• Cindy Zuleger

  University of Wisconsin Carbone Cancer Center

  114 shared

• Jacquelyn A. Hank

  University of Wisconsin–Madison

  110 shared

• Erik A. Ranheim

  University of Wisconsin–Madison

  62 shared

• Zachary S. Morris

  University of Wisconsin–Madison

  61 shared

• Michael A. Newton

  University of Wisconsin–Madison

  60 shared

• KyungMann Kim

  University of Wisconsin–Madison

  57 shared

• William J. Maples

  54 shared

Education

• M.D., Medicine

  University of Vermont, College of Medicine

• Other, Internal Medicine

  University of Wisconsin Hospital and Clinics

• Other, Tumor Immunology

  University of Wisconsin–Madison

• Other, Medical Oncology and Biotherapy

  University of Wisconsin Carbone Cancer Center

Awards & honors

• Professionalism Award from Department of Medicine housestaff
• UW Health Patient Experience Physician Champion Award
• listed by the Best Doctors in America organization

Similar researchers at University of Wisconsin-Madison

• Bret Benally Thompsonh-8